NO20002697D0 - Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen - Google Patents

Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen

Info

Publication number
NO20002697D0
NO20002697D0 NO20002697A NO20002697A NO20002697D0 NO 20002697 D0 NO20002697 D0 NO 20002697D0 NO 20002697 A NO20002697 A NO 20002697A NO 20002697 A NO20002697 A NO 20002697A NO 20002697 D0 NO20002697 D0 NO 20002697D0
Authority
NO
Norway
Prior art keywords
diagnostic
variation
diseases caused
therapeutic preparation
lkb1 gene
Prior art date
Application number
NO20002697A
Other languages
English (en)
Other versions
NO20002697L (no
Inventor
Dieter E Jenne
Jun-Ichi Nezu
Original Assignee
Chugai Res Inst Molecular Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Res Inst Molecular Med filed Critical Chugai Res Inst Molecular Med
Publication of NO20002697D0 publication Critical patent/NO20002697D0/no
Publication of NO20002697L publication Critical patent/NO20002697L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20002697A 1997-11-27 2000-05-26 Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen NO20002697L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34425697 1997-11-27
JP28035798 1998-10-01
PCT/JP1998/005357 WO1999028459A1 (fr) 1997-11-27 1998-11-27 Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1

Publications (2)

Publication Number Publication Date
NO20002697D0 true NO20002697D0 (no) 2000-05-26
NO20002697L NO20002697L (no) 2000-07-27

Family

ID=26553739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002697A NO20002697L (no) 1997-11-27 2000-05-26 Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen

Country Status (6)

Country Link
US (1) US6800436B1 (no)
EP (1) EP1036844A4 (no)
AU (1) AU750564B2 (no)
CA (1) CA2311414A1 (no)
NO (1) NO20002697L (no)
WO (1) WO1999028459A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4951300A (en) 1999-05-31 2000-12-18 Chugai Research Institute For Molecular Medicine, Inc. Lkb1 gene knockout animals
WO2002006520A1 (en) * 2000-07-19 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound
ES2313029T3 (es) * 2003-06-17 2009-03-01 Medical Research Council Metodo para evaluar la actividad de fosforilacion de lkb1.
CN102747141A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
EP1907577A4 (en) * 2005-06-30 2009-05-13 Syngenta Participations Ag PROCESS FOR SCREENING TO GENE SPECIFIC HYBRIDIZATION POLYMORPHISMS (GSHP) AND THEIR USE IN GENETIC MAPPING AND MARKET DEVELOPMENT
SG183155A1 (en) * 2010-02-03 2012-09-27 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014254059B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5827726A (en) 1995-03-16 1998-10-27 Chugai Seiyaku Kabushiki Kaisha DNA coding protein kinase
JPH08308586A (ja) * 1995-03-16 1996-11-26 Chugai Pharmaceut Co Ltd プロテインキナーゼをコードするｄｎａ

Also Published As

Publication number Publication date
CA2311414A1 (en) 1999-06-10
EP1036844A4 (en) 2002-12-04
AU1262099A (en) 1999-06-16
NO20002697L (no) 2000-07-27
WO1999028459A1 (fr) 1999-06-10
US6800436B1 (en) 2004-10-05
AU750564B2 (en) 2002-07-25
EP1036844A1 (en) 2000-09-20

Similar Documents

Publication Publication Date Title
NO20002697L (no) Diagnostisk metode, diagnostisk reagens og terapeutisk preparat for sykdommer forÕrsaket av variasjon i LKB1-gen
ATE464050T1 (de) Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
NO20016364D0 (no) Fremgangsmåte og anordning for noninvasiv blodanalysemåling
NO20012689D0 (no) Nye fluider og teknikker for matriks syrebehandling
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
NO20003288L (no) Preparat for behandling av respiratoriske sykdommer og hudsykdommer, omfattende minst en leukotrienantagonist og minst ett antihistamin
AU7466500A (en) Method and apparatus for detecting blood characteristics including hemoglobin
DE60336264D1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung
DE69632143D1 (de) Ball und methode zu seiner herstellung
AU2002313947A1 (en) Medicinal agent and method for curing diseases accompanied with vascular dystonia
DE69815529D1 (de) Acrylonitril-derivate, verfahren zu ihrer herstellung und diese enthaltende schädlingsbekämpfungsmittel
IS5852A (is) Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum
ATE267202T1 (de) 1,4-diazabicyclo(3.2.2)nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
AU2003272341A1 (en) Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
AU7041400A (en) Health care system and method thereof
AU6225999A (en) Disposable training pant, apparatus and method for manufacturing it
AU2002239664A1 (en) Method for drug development using individual patient response
WO2002063951A3 (en) Human disease modeling using somatic gene transfer
AU2002332102A1 (en) System, method, and apparatus for disease susceptibility testing
DE69531054D1 (de) Landwirtschaftliche chemische präparate und verfahren zu ihrer herstellung
DE60003662D1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE294181T1 (de) (3,4-a:3,4-c)carbazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU2003276727A1 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
EP1539957A4 (en) NEW DIAGNOSTIC AND THERAPY PROCEDURES AND REAGENTS FOR THIS
EP1483407A4 (en) THERAPY AND DIAGNOSTIC PROCEDURES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application